Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

Foundayo

Metabolic & Weight Loss

Molecular Dossier

  • Rank Index: 46
  • Status: FDA Approved
  • What does this mean?
  • Molecular Structure: MW: ~456 Da | Small-molecule, non-peptidic | Class: Allosteric GLP-1R modulator

About Foundayo

Foundayo (orforglipron) is a once-daily small-molecule (non-peptide) GLP-1 receptor agonist approved by the FDA in January 2026. Unlike peptide GLP-1s (semaglutide, tirzepatide, retatrutide), orforglipron is a synthetic organic compound that can be taken orally without food or water restrictions — a major practical advantage over Wegovy oral (which requires fasting conditions). Clinical trial data (Phase 2b) showed approximately 8–12% body weight reduction at therapeutic doses. The compound is non-peptidic, enabling oral administration and reducing immunogenicity risk. Foundayo represents a paradigm shift in GLP-1 therapeutics: small-molecule GLP-1 agonists had long been considered intractable due to the receptor's large orthosteric binding pocket, but orforglipron successfully achieved oral bioavailability through allosteric modulation. As of 2026, Foundayo is a first-line option for patients who prefer or require oral administration without dietary constraints. Gastrointestinal side effects (nausea, vomiting, diarrhea) are expected with all GLP-1 agonists but are dose-dependent. Cardiovascular outcomes trials are pending.

Clinical Focus

Small-Molecule Oral GLP-1 Agonist — No Food/Water Restrictions

Archival Aliases

Orforglipron, Rybelsus analogue (non-peptidic)

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~456 Da | Small-molecule, non-peptidic | Class: Allosteric GLP-1R modulator
Primary Pathway Metabolic & Weight Loss
Research Phase FDA Approved

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] lilly.com
[REF 2] fda.gov
[REF 3] pubmed.ncbi.nlm.nih.gov

Data Verified: 2026-05-07

Synergistic Matrix